A Phase 1 Dose-Escalation Study of Filanesib Plus Bortezomib and Dexamethasone in Patients With Recurrent/Refractory Multiple Myeloma

BACKGROUND: Filanesib is a kinesin spindle protein inhibitor that has demonstrated encouraging activity in patients with recurrent/refractory multiple myeloma. Preclinical synergy with bortezomib was the rationale for the current phase 1 study. METHODS: The current study was a multicenter study with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Chari, Ajai, Htut, Myo, Zonder, Jeffrey A., Fay, Joseph W., Jakubowiak, Andrzej J., Levy, Joan B., Lau, Kenneth, Burt, Steven M., Tunquist, Brian J., Hilder, Brandi W., Rush, Selena A., Walker, Duncan H., Ptaszynski, Mieke, Kaufman, Jonathan L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6857452/
https://ncbi.nlm.nih.gov/pubmed/27433944
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30174
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados